8 results
AACE/ACE 2018 Glycemic Control Algorithm

#AACE #2018 #Glycemic #Diabetes #DM2 #Control #Medication #Algorithm #Endocrinology #PrimaryCare #Management
Control Algorithm ... #AACE #2018 # ... Glycemic #Diabetes ... #DM2 #Control # ... #Endocrinology
Profiles of Antidiabetic Medications - AACE 2018 

#Antidiabetic #Medications #Profiles #SideEffects #Table #DecisionAid #Orals #DM2 #Diabetes
Medications - AACE 2018 ... DecisionAid #Orals #DM2 ... #Diabetes #Endocrinology ... #Pharmacology #
Diabetes Combination Tablets - Estimated A1c Lowering 
Metformin + DPP4 
• Janumet (metformin + sitagliptin) 
•
Diabetes Combination ... Metformin + DPP4 ... Tablets #Oral #DM2 ... #Pharmacology # ... Pills #Endocrinology
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
DPP-4 Inhibitors ... - Pharmacology ... #Inhibitors #Pharmacology ... #Summary #DM2 # ... diabetes #endocrinology
DPP4 Inhibitors - Normal and Renal Dosing

Increase Incretins (GLP-I & GIP) -> Stimulates Insulin, Inhibits Glucagon
DPP4 Inhibitors ... linagliptin) 5 mg DPP4 ... Renal #Dosing #Pharmacology ... #Management #Diabetes ... #DM2 #Endocrinology
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Diabetes Mellitus ... Sulfonylurea, TZD, DPP ... #Mellitus #DM2 ... #Medications #pharmacology ... comparison #table #endocrinology
SGLT2 Inhibitors 
SGLT2 inhibitors are the newest class of anti-diabetic medications, with the first one (Canagliflozin)
class of anti-diabetic ... being approved in 2013 ... SGLT2 #Inhibitors #Pharmacology ... #Medications #DM2 ... #Diabetes #Endocrinology
GLP-1 Agonists

Adlyxin (Lixisenatide) Daily
Bydureon (Exenatide ER) Weekly 
Ozempic (Semaglutide) Weekly 
Trulicity (Dulaglutide) Weekly 
Victoza (Liraglutide) Daily
to treat Type 2 Diabetes ... very similar to DPP4s ... GLP1 #Agonists #Pharmacology ... #Dosing #Diabetes ... #DM2 #Endocrinology